{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-081324","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.402630+00:00","generated_at":"2026-06-10T02:37:46.691975+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Blue Water Biotech appoints Dr. Neil Campbell as CEO and Bruce Harmon as CFO effective October 4, 2023","bullets":["Dr. Neil Campbell appointed President & CEO and board member; replaces prior plan for James Sapirstein as Interim Executive Chairman.","Bruce Harmon appointed CFO, replacing Jon Garfield who resigned; Garfield receives $72,500 severance.","Campbell receives $75,000 signing bonus, $475,000 base salary, option to purchase 3% of outstanding shares.","Harmon receives $325,000 base salary, option to purchase 1% of outstanding shares.","James Sapirstein appointed non-executive Chairman of the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-081324","json":"https://secwatch.observer/filing/0001213900-23-081324.json","markdown":"https://secwatch.observer/filing/0001213900-23-081324.md","text":"https://secwatch.observer/filing/0001213900-23-081324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383-8k_bluewater.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:37:46.691975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"745f5983d0","claim":"Jon Garfield resigned as Chief Financial Officer at Onconetix, Inc..","evidence_excerpt":"Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f0709191e4","claim":"Neil Campbell was appointed as President and Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}